REPL - Replimune Group Inc logo

REPL

Replimune Group Inc

Rev โ€”top 1%5Y
Hold

Replimune Group develops oncolytic immunotherapies for cancer treatment, utilizing engineered viruses to activate the immune system. Its lead products, RP1, RP2, and RP3, target various solid tumors by enhancing immune responses against cancer cells.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago โ†’$494today

Score Overview

1 Year
Scoreโ€”
Net Growth-26.95%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-288.20%
Net TrendNever
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-8x
Net TrendNever
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Replimune Group Inc fundamental performance

Across Replimune Group Inc's full reported history, from 2019 to 2026, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 30M to -$ 313M. Revenue increased in 0% of the years measured; net income in 0%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 15.24โ€”
1 Year2025-08-12
$ 5.25190.29%
5 Years2021-08-12
$ 30.84-50.58%
All Time2018-07-20
$ 15.160.53%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 313M$ 268M
2025$ 0.00-$ 247M$ 483M
2024$ 0.00-$ 215M$ 420M
2023$ 0.00-$ 174M$ 583M
2022$ 0.00-$ 118M$ 395M
2021$ 0.00-$ 80M$ 476M
2020$ 0.00-$ 52M$ 168M
2019$ 0.00-$ 30M$ 134M

Explore beyond REPL

You're looking at Replimune Group Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies